chevron_leftBack
As of 14 June 2026, Agentix Corp. has a market cap of $1.52M USD, ranking #47753 globally and #6094 in the United States.
It ranks #4233 in the Healthcare sector, and #1340 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$1.52MUSD
Enterprise Value
$1.87MUSD
Net Income (TTM)
-$590.29KUSD
PB Ratio
-0.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Riazul Huda
open_in_new
Founded
2020
Website
agentixcorp.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -13% | -52% | -9.5% | -22% | -24% | -24% |
Upcoming Earnings
Earnings Date
Tue, Jul 14
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
AGTX
Agentix Corp
ISIN: US00848A1034
Shares Out.:
Shares Outstanding:
40.067M1
Shares Float:
31.687M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.0380 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Agentix Corp.
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was founded in 2020 and is based in Dana Point, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
50M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
36M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
24M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
18M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
10M%
|
19.5
|
|
NYSE: BMY
|
$117.58B
8M%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
21M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
19M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
18M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
12M%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
7M%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
7M%
80.96B GBP
|
14.6
|
chevron_leftBack